Source

Department of Medicine, Viral Hepatitis Center, University of California San Francisco, Room S-357, 513 Parnassus Avenue, San Francisco, CA 94143, USA.

Abstract

A significant proportion of treatment-experienced hepatitis C virus genotype 1 (GT1) patients will not achieve systemic vascular resistance with protease inhibitor-triple therapy, and so the need for alternative therapies for these patients remains high. The aim of this article is to provide a critical evaluation of the available data, highlighting the knowledge gaps and providing a practical framework for making treatment decisions in treatment-experienced GT1 patients with currently approved drugs.